Mechanistic basis of enzyme-targeted drugs

Biochemistry

Volumn 44, Issue 15, 2005, Pages 5561-5571

  Robertson, James G ^a  

^a Softzymics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; DATABASE SYSTEMS; DNA; DRUG PRODUCTS; FUNGI; HORMONES; VIRUSES;

DRUG TRAPS; ENZYME-TARGETED DRUGS; HORMONE RECEPTORS; ION CHANNELS;

ENZYMES;

4 METHYLPYRAZOLE; ACARBOSE; ACETAZOLAMIDE; ACETYLSALICYLIC ACID; ACICLOVIR; BACITRACIN; CARBIDOPA; CASPOFUNGIN; CIPROFLOXACIN; CYCLOSERINE; DAPSONE; DISULFIRAM; ENTACAPONE; ETHAMBUTOL; FINASTERIDE; LEFLUNOMIDE; METHOTREXATE; MIGLITOL; MIGLUSTAT; NITISINONE; PENTOSTATIN; PYRIDOSTIGMINE; RIFAPENTINE; SILDENAFIL; TAZOBACTAM; THEOPHYLLINE; TOPOTECAN; TRANYLCYPROMINE; TRILOSTANE; UNINDEXED DRUG; ZILEUTON;

AMINO ACID SEQUENCE; CATALYSIS; CORRELATION ANALYSIS; DRUG DESIGN; DRUG MARKETING; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYMOLOGY; PRIORITY JOURNAL; REVIEW; STOICHIOMETRY;

ANIMALS; DATABASES, FACTUAL; DRUG DESIGN; ENZYME ACTIVATION; ENZYME INHIBITORS; ENZYMES; HUMANS; MOLECULAR STRUCTURE; SUBSTRATE SPECIFICITY;

BACTERIA (MICROORGANISMS);

EID: 17244362388     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi050247e     Document Type: Review

References (158)

1. International Human Genome Sequence Consortium (2004) Finishing the euchromatic sequence of the human genome, Nature 431, 931-945.
2. Drews, J. (2000) Drug discovery: A historical perspective, Science 287, 1960-1964.
3. Center for Drug Evaluation and Research (2002) New Molecular Entities (NMEs) Reports, http://www.fda.gov/cder/rdmt/default.htm.
4. Oneil, M. J., Smith, A., and Heckelman, P. E., Eds. (2001) The Merck Index, 13th ed., Merck Research Laboratories, Piscataway, NJ.
5. Hardman, J. G., Limbird, L. E., and Gilman, A. G. (2001) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 10th ed., McGcaw-Hill, New York.
6. DiPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., and Posey, L. M., Eds. (2002) Pharmacotherapy: A Pathophysiologic Approach, 5th ed., McGraw-Hill, New York.
7. McEvoy, G. K. (2002) AHFS Drug Information, American Society of Health-System Pharmacists.
8. Center for Drug Evaluation and Research (2003) Electronic Orange Book, http://www.fda.gov/cder/orange/obreadme.htm.
9. Tipper, D. J., and Strominger, J. L. (1965) Mechanism of action of penicillins: A proposal based on their structural similarity to acyl-D-alanyl-D-alanine, Proc. Natl. Acad. Sci. U.S.A. 54, 1133-1141.
10. Istvan, E. S., and Deisenhofer, J. (2001) Structural mechanism for statin inhibition of HMG-CoA reductase, Science 292, 1160-1164.
11. Lienhard, G. E. (1973) Enzymatic catalysis and transition-state theory, Science 180, 149-154.
12. Wolfenden, R. (1976) Transition state analog inhibitors and enzyme catalysis, Annu. Rev. Biophys. Bioeng. 5, 271-306.
13. Radzicka, A., and Wolfenden, R. (1995) Transition state and multisubstrate analog inhibitors, Methods Enzymol. 249, 284-312.
14. Agarwal, R. P., Spector, T., and Parks, R. E., Jr. (1977) Tight-Binding Inhibitors. IV. Inhibition of Adenosine Deaminases by Various Inhibitors, Biochem. Pharmacol. 26, 359-367.
15. Cushman, D. W., Ondetti, M. A., Gordon, E. M., Natarajan, S., Karanewsky, D. S., Krapcho, J., and Petrillo, E. W., Jr. (1987) Rational design and biochemical utility of specific inhibitors of angiotensin-converting enzyme, J. Cardiovasc. Pharmacol. 10, S17-S30.
16. Byers, L. D., and Wolfenden, R. (1973) Binding of the by-product analog benzylsuccinic acid by carboxypeptidase A, Biochemistry 12, 2070-2078.
17. Roberts, N. A., Martin, J. A., Kinchington, D., Broadhurst, A. V., Craig, J. C., Duncan, I. B., Galpin, S. A., Handa, B. K., Kay, J., Krohn, A., Lambert, R. W., Merrett, J. H., Mills, J. S., Parkes, K. E. B., Redshaw, S., Ritchie, A. J., Taylor, D. L., Thomas, G. S., and Machin, P. J. (1990) Rational design of peptide-based HIV proteinase inhibitors, Science 248, 358-361.
18. Chong, A. K., Pegg, M. S., Taylor, N. R., and von Itzstein, M. (1992) Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus, Eur. J. Biochem. 207, 335-343.
19. von Iztstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., Colman, P. M., Varghese, J. N., Ryan, D. M., Woods, J. M., Bethell, R. C., Hotham, V. J., Cameron, J. M., and Penn, C. R. (1993) Rational design of potent sialidase-based inhibitors of influenza virus replication, Nature 363, 418-423.
20. Schramm, V. L. (2005) Enzymatic transition states: Thermodynamics, dynamics and analogue design, Arch. Biochem. Biophys. 433, 13-26.
21. Evans, G. B., Furneaux, R. H., Schramm, V. L., Singh, V., and Tyler, P. C. (2004) Targeting the polyamine pathway with transition-state analogue inhibitors of 5′-methylthioadenosine phosphorylase, J. Med. Chem. 47, 3275-3281.
22. Lu, W. P., Kincaid, E., Sun, Y., and Bauer, M. D. (2001) Kinetics of β-lactam interactions with penicillin-susceptible and -resistant penicillin-binding protein 2x proteins from Streptococcus pneumoniae. Involvement of acylation and deacylation in β-lactam resistance, J. Biol. Chem. 276, 31494-31501.
23. Goffin, C., and Ghuysen, J. M. (1998) Multimodular penicillin-binding proteins: An enigmatic family of orthologs and paralogs, Microbiol. Mol. Biol. Rev. 62, 1079-1093.
24. Christensen, H., Martin, M. T., and Waley, S. G. (1990) β-Lactamases as fully efficient enzymes. Determination of all the rate constants in the acyl-enzyme mechanism, Biochem. J. 266, 853-861.
25. Kahan, F. M., Kahan, J. S., Cassidy, P. J., and Kropp, H. (1974) The mechanism of action of fosfomycin (phosphonomycin), Ann. N.Y. Acad. Sci. 235, 364-386.
26. Thomas, A. M., Ginj, C., Jelesarov, I., Amrhein, N., and Macheroux, P. (2004) Role of K22 and R120 in the covalent binding of the antibiotic fosfomycin and the substrate-induced conformational change in UDP-N-acetylglucosamine enolpyruvyl transferase, Eur. J. Biochem. 271, 2682-2690.
27. Hemler, M., and Lands, W. E. (1976) Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme, J. Biol. Chem. 251, 5575-5579.
28. Van Der Ouderaa, F. J., Buytenhek, M., Nugteren, D. H., and Van Dorp, D. A. (1980) Acetylation of prostaglandin endoperoxide synthetase with acetylsalicylic acid, Eur. J. Biochem. 109, 1-8.
29. Siiteri, P. K., and Thompson, E. A. (1975) Studies of human placental aromatase, J. Steroid Biochem. 6, 317-322.
30. Brueggemeier, R. W. (2001) Aromatase, aromatase inhibitors, and breast cancer, Am. J. Ther. 8, 333-344.
31. Finberg, J. P., and Youdim, M. B. (1983) Selective MAO A and B inhibitors: Their mechanism of action and pharmacology, Neuropharmacology 22, 441-446.
32. Fowler, C. J., Mantle, T. J., and Tipton, K. F. (1982) The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, 1-deprenyl and pargyline, Biochem. Pharmacol. 31, 3555-3561.
33. Santi, D. V., McHenry, C. S., and Sommer, H. (1974) Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate, Biochemistry 13, 471-481.
34. Poulin, R., Lu, L., Ackermann, B., Bey, P., and Pegg, A. E. (1992) Mechanism of the irreversible inactivation of mouse ornithine decarboxylase by α-difluoromethylornithine. Characterization of sequences at the inhibitor and coenzyme binding sites, J. Biol. Chem. 267, 150-158.
35. Grishin, N. V., Osterman, A. L., Brooks, H. B., Phillips, M. A., and Goldsmith, E. J. (1999) X-ray structure of ornithine decarboxylase from Trypanosoma brucei: The native structure and the structure in complex with α-difluoromethylornithine, Biochemistry 38, 15174-15184.
36. Wang, E., and Walsh, C. (1978) Suicide substrates for the alanine racemase of Escherichia coli B, Biochemistry 17, 1313-1321.
37. Fenn, T. D., Stamper, G. F., Morollo, A. A., and Ringe, D. (2003) A side reaction of alanine racemase: Transamination of cycloserine, Biochemistry 42, 5775-5783.
38. Richardson, P., Hawkey, C. J., and Stack, W. A. (1998) Proton Pump Inhibitors: Pharmacology and Rationale for Use in Gastrointestinal Disorders, Drugs 56, 307-335.
39. Hadvary, P., Sidler, W., Meister, W., Vetter, W., and Wolfer, H. (1991) The lipase inhibitor tetrahydrolipstatin binds covalently to the putative active site serine of pancreatic lipase, J. Biol. Chem. 266, 2021-2027.
40. Winkler, F. K., D'Arcy, A., and Hunziker, W. (1990) Structure of human pancreatic lipase, Nature 343, 771-774.
41. Baker, C. H., Banzon, J., Bollinger, J. M., Stubbe, J., Samano, V., Robins, M. J., Lippert, B., Jarvi, E., and Resvick, R. (1991) 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′- difluorocytidine 5′-diphosphates: Potent mechanism-based inhibitors of ribonucleotide reductase, J. Med. Chem. 34, 1879-1884.
42. Nagasaka, A., and Hidaka, H. (1976) Effect of antithyroid agents 6-propyl-2-thiouracil and 1-mehtyl-2-mercaptoimidazole on human thyroid iodine peroxidase, J. Clin. Endocrinol. Metab. 43, 152-158.
43. Engler, H., Taurog, A., Luthy, C., and Dorris, M. L. (1983) Reversible and irreversible inhibition of thyroid peroxidase-catalyzed iodination by thioureylene drugs, Endocrinology 112, 86-95.
44. Kohrle, J. (1999) Local activation and inactivation of thyroid hormones: The deiodinase family, Mol. Cell. Endocrinol. 151, 103-119.
45. Berry, M. J., Kieffer, J. D., Harney, J. W., and Larsen, P. R. (1991) Selenocysteine confers the biochemical properties characteristic of the type I iodothyronine deiodinase, J. Biol. Chem. 266, 14155-14158.
46. Yamada, T., Chopra, I. J., and Kaplowitz, N. (1981) Inhibition of rat hepatic thyroxine 5′-monodeiodinase by propylthiouracil: Relation to site of interaction of thyroxine and glutathione, J. Endocrinol. Invest. 4, 379-387.
47. Kitson, T. M. (1975) The effect of disulfiram on the aldehyde dehydrogenases of sheep liver, Biochem. J. 151, 407-412.
48. Tomlinson, A. J., Johnson, K. L., Lam-Holt, J., Mays, D. C., Lipsky, J. J., and Naylor, S. (1997) Inhibition of human mitochondrial aldehyde dehydrogenase by the disulfiram metabolite S-methyl-N,N-diethylthiocarbamoyl sulfoxide: Structural characterization of the enzyme adduct by HPLC-tandem mass spectrometry, Biochem. Pharmacol. 54, 1253-1260.
49. Shen, M. L., Johnson, K. L., Mays, D. C., Lipsky, J. J., and Naylor, S. (2001) Determination of in vivo adducts of disulfiram with mitochondrial aldehyde dehydrogenase, Biochem. Pharmacol. 61, 537-545.
50. Jin, L., Abrahams, J. P., Skinner, R., Petitou, M., Pike, R. N., and Carrell, R. W. (1997) The anticoagulant activation of antithrombin by heparin, Proc. Natl. Acad. Sci. U.S.A. 94, 14683-14688.
51. Hoylaerts, M., Owen, W. G., and Collen, D. (1984) Involvement of heparin chain length in the heparin-catalyzed inhibition of thrombin by antithrombin III, J. Biol. Chem. 259, 5670-5677.
52. Rezaie, A. R., and Olson, S. T. (2000) Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by promoting the assembly of an intermediate heparin-antithrombin-factor Xa bridging complex. Demonstration by rapid kinetics studies, Biochemistry 39, 12083-12090.
53. Braun, P. J., Dennis, S., Hofsteenge, J., and Stone, S. R. (1988) Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin, Biochemistry 27, 6517-6522.
54. Holme, E., and Lindstedt, S. (1998) Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione), J. Inherited Metab. Dis. 21, 507-517.
55. Kavana, M., and Moran, G. R. (2003) Interaction of (4-hydroxyphenyl) pyruvate dioxygenase with the specific inhibitor 2-[2-nitro-4-(trifluoromethyl) benzoyl]-1,3-cyclohexanedione, Biochemistry 42, 10238-10245.
56. Fasco, M. J., Principe, L. M., Walsh, W. A., and Friedman, P. A. (1983) Warfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomes, Biochemistry 22, 5655-5660.
57. Fasco, M. J., and Principe, L. M. (1982) R- and S-Warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat, J. Biol. Chem. 257, 4894-4901.
58. Hughes, J., and Mellows, G. (1980) Interaction of pseudomonic acid A with Escherichia coli B isoleucyl-tRNA synthetase, Biochem. J. 191, 209-219.
59. Pope, A. J., Moore, K. J., McVey, M., Mensah, L., Benson, N., Osbourne, N., Broom, N., Brown, M. J., and O'Hanlon, P. (1998) Characterization of isoleucyl-tRNA synthetase from Staphylococcus aureus. II. Mechanism of inhibition by reaction intermediate and pseudomonic acid analogues studied using transient and steady-state kinetics, J. Biol. Chem. 273, 31691-31701.
60. Furman, P. A., St Clair, M. H., and Spector, T. (1984) Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase, J. Biol. Chem. 259, 9575-9579.
61. Bull, H. G., Calvo, M. G., Andersson, S., Baginsky, W. F., Chan, H. K., Ellsworth, D. E., Miller, R. R., Stearns, R. A., Bakshi, R. K., Rasmusson, G. H., Tolman, R. L., Myers, R. W., Kozarich, J. W., and Harris, G. S. (1996) Mechanism-Based Inhibition of Human Steroid 5a-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor, J. Am. Chem. Soc. 118, 2359-2365.
62. Rozwarski, D. A., Grant, G. A., Barton, D. H., Jacobs, W. R., Jr., and Sacchettini, J. C. (1998) Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis, Science 279, 98-102.
63. Quemard, A., Dessen, A., Sugantino, M., Jacobs, W. R., Jr., Sacchettini, J. C., and Blanchard, J. S. (1996) Binding of Catalase-Peroxidase-Activated Isoniazid to Wild-Type and Mutant Mycobacterium tuberculosis Enoyl-ACP Reductases, J. Am. Chem. Soc. 118, 1561-1562.
64. Harrison, R. (2002) Structure and function of xanthine oxidoreductase: Where are we now? Free Radical Biol. Med. 33, 774-797.
65. Silverman, R. B. (1992) The Organic Chemistry of Drug Design and Drug Action, Academic Press, San Diego.
66. Massey, V., Komai, H., Palmer, G., and Elion, G. B. (1970) On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines, J. Biol. Chem. 245, 2837-2844.
67. Spector, T., and Johns, D. G. (1970) Stoichiometric inhibition of reduced xanthine oxidase by hydroxypyrazolo [3,4-d]pyrimidines, J. Biol. Chem. 245, 5079-5085.
68. Sintchak, M. D., and Nimmesgern, E. (2000) The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors, Immunopharmacology 47, 163-184.
69. Fleming, M. A., Chambers, S. P., Connelly, P. R., Nimmesgern, E., Fox, T., Bruzzese, F. J., Hoe, S. T., Fulghum, J. R., Livingston, D. J., Stuver, C. M., Sintchak, M. D., Wilson, K. P., and Thomson, J. A. (1996) Inhibition of IMPDH by mycophenolic acid: Dissection of forward and reverse pathways using capillary electrophoresis, Biochemistry 35, 6990-6997.
70. Drlica, K., and Zhao, X. (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones, Microbiol. Mol. Biol. Rev. 61, 377-392.
71. Higgins, P. G., Fluit, A. C., and Schmitz, F. J. (2003) Fluoroquinolones: Structure and target sites, Curr. Drug Targets 4, 181-190.
72. Osheroff, N. (1989) Biochemical basis for the interactions of type I and type II topoisomerases with DNA, Pharmacol. Ther. 41, 223-241.
73. Redinbo, M. R., Stewart, L., Kuhn, P., Champoux, J. J., and Hol, W. G. (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA, Science 279, 1504-1513.
74. Fan, Y., Weinstein, J. N., Kohn, K. W., Shi, L. M., and Pommier, Y. (1998) Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin, J. Med. Chem. 41, 2216-2226.
75. Sander, M., and Hsieh, T. (1983) Double strand DNA cleavage by type II DNA topoisomerase from Drosophila melanogaster, J. Biol. Chem. 258, 8421-8428.
76. Wigley, D. B. (1996) A wasp head with a relaxing bite, Structure 4, 117-120.
77. Yang, W., Gao, X., and Wang, B. (2003) Boronic Acid Compounds as Potential Pharmaceutical Agents, Med. Res. Rev. 23, 346-368.
78. i value in the femtomolar range, Biochemistry 30, 8165-8170.
79. Adams, J. (2002) Development of the proteasome inhibitor PS-341. Oncologist 7, 9-16.
80. Palombella, V. J., Conner, E. M., Fuseler, J. W., Destree, A., Davis, J. M., Laroux, F. S., Wolf, R. E., Huang, J., Brand, S., Elliott, P. J., Lazarus, D., McCormack, T., Parent, L., Stein, R., Adams, J., and Grisham, M. B. (1998) Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis, Proc. Natl. Acad. Sci. U.S.A. 95, 15671-15676.
81. Spence, R. A., Kati, W. M., Anderson, K. S., and Johnson, K. A. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors, Science 267, 988-993.
82. Grimsby, J., Sarabu, R., Corbett, W. L., Haynes, N. E., Bizzarro, F. T., Coffey, J. W., Guertin, K. R., Hilliard, D. W., Kester, R. F., Mahaney, P. E., Marcus, L., Qi, L., Spence, C. L., Tengi, J., Magnuson, M. A., Chu, C. A., Dvorozniak, M. T., Matschinsky, F. M., and Grippo, J. F. (2003) Allosteric activators of glucokinase: Potential role in diabetes therapy, Science 301, 370-373.
83. Glaser, B., Kesavan, P., Heyman, M., Davis, E., Cuesta, A., Buchs, A., Stanley, C. A., Thornton, P. S., Permutt, M. A., Matschinsky, F. M., and Herold, K. C. (1998) Familial hyperinsulinism caused by an activating glucokinase mutation, N. Engl. J. Med. 338, 226-230.
84. Christesen, H. B., Jacobsen, B. B., Odili, S., Buettger, C., Cuesta-Munoz, A., Hansen, T., Brusgaard, K., Massa, O., Magnuson, M. A., Shiota, C., Matschinsky, F. M., and Barbetti, F. (2002) The second activating glucokinase mutation (A456V): Implications for glucose homeostasis and diabetes therapy, Diabetes 51, 1240-1246.
85. Lee, H., Hanes, J., and Johnson, K. A. (2003) Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase, Biochemistry 42, 14711-14719.
86. McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., Park, Y., Savarese, B., Kleiner, D., Tsokos, M., Luciano, C., et al. (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B, N. Engl. J. Med. 333, 1099-1105.
87. Feldmesser, M., Kress, Y., Mednick, A., and Casadevall, A. (2000) The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans, J. Infect. Dis. 182, 1791-1795.
88. Coirini, H., Gouezou, M., Delespierre, B., Liere, P., Pianos, A., Eychenne, B., Schumacher, M., and Guennoun, R. (2003) Characterization and regulation of the 3β-hydroxysteroid dehydrogenase isomerase enzyme in the rat sciatic nerve, J. Neurochem. 84, 119-126.
89. Corbin, J. D., and Francis, S. H. (1999) Cyclic GMP phosphodiesterase-5: Target of sildenafil, J. Biol. Chem. 274, 13729-13732.
90. Londesborough, J. (1977) Characterization of an adenosine 3′:5′-cyclic monophosphate phosphodiesterase from baker's yeast. Its binding to subcellular particles, catalytic properties and gel-filtration behaviour, Biochem. J. 163, 467-476.
91. Hall, M. G., Wilks, M. F., Provan, W. M., Eksborg, S., and Lumholtz, B. (2001) Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4- fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers, Br. J. Clin. Pharmacol 52, 169-177.
92. Andriole, G., Bruchovsky, N., Chung, L. W., Matsumoto, A. M., Rittmaster, R., Roehrborn, C., Russell, D., and Tindall, D. (2004) Dihydrotestosterone and the prostate: The scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia, J. Urol. 172, 1399-1403.
93. Jann, M. W., Shirley, K. L., and Small, G. W. (2002) Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors, Clin. Pharmacokinet. 41, 719-739.
94. Merkler, D. J., Brenowitz, M., and Schramm, V. L. (1990) The rate constant describing slow-onset inhibition of yeast AMP deaminase by coformycin analogues is independent of inhibitor structure, Biochemistry 29, 8358-8364.
95. Mustata, G. I., Scares, T. A., and Briggs, J. M. (2003) Molecular dynamics studies of alanine racemase: A structural model for drug design, Biopolymers 70, 186-200.
96. Plapp, B. V., Leidal, K. G., Smith, R. K., and Murch, B. P. (1984) Kinetics of inhibition of ethanol metabolism in rats and the rate-limiting role of alcohol dehydrogenase, Arch. Biochem. Biophys. 230, 30-38.
97. Lipsky, J. J., Shen, M. L., and Naylor, S. (2001) In vivo inhibition of aldehyde dehydrogenase by disulfiram, Chem.-Biol. Interact. 130-132, 93-102.
98. Ferey-Roux, G., Perrier, J., Forest, E., Marchis-Mouren, G., Puigserver, A., and Santimone, M. (1998) The human pancreatic α-amylase isoforms: Isolation, structural studies and kinetics of inhibition by acarbose, Biochim. Biophys. Acta 1388, 10-20.
99. Sels, J. P., Huijberts, M. S., and Wolffenbuttel, B. H. (1999) Miglitol, a new α-glucosidase inhibitor, Expert Opin. Pharmacother. 1, 149-156.
100. Mallinger, A. G., and Smith, E. (1991) Pharmacokinetics of monoamine oxidase inhibitors, Psychopharmacol. Bull. 27, 493-502.
101. Belanger, A. E., Besra, G. S., Ford, M. E., Mikusova, K., Belisle, J. T., Brennan, P. J., and Inamine, J. M. (1996) The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol, Proc. Natl. Acad. Sci. U.S.A. 93, 11919-11924.
102. Bell, R. L., Young, P. R., Albert, D., Lanni, C., Summers, J. B., Brooks, D. W., Rubin, P., and Carter, G. W. (1992) The discovery and development of zileuton: An orally active 5-lipoxygenase inhibitor, Int. J. Immunopharmacol. 14, 505-510.
103. Burkhard, P., Dominici, P., Borri-Voltattorni, C., Jansonius, J. N., and Malashkevich, V. N. (2001) Structural insight into Parkinson's disease treatment from drug-inhibited DOPA decarboxylase, Nat. Struct. Biol. 8, 963-967.
104. Livermore, D. M. (1993) Determinants of the activity of β-lactamase inhibitor combinations, J. Antimicrob. Chemother. 31 (Suppl. A), 9-21.
105. Wells, J. W., Kandel, S. I., Kandel, M., and Gornall, A. G. (1975) The esterase activity of bovine carbonic anhydrase B above pH 9. Reversible and covalent inhibition by acetozolamide, J. Biol. Chem. 250, 3522-3530.
106. Kurth, M. C., and Adler, C. H. (1998) COMT inhibition: A new treatment strategy for Parkinson's disease, Neurology 50, S3-S14.
107. Platt, F. M., Neises, G. R., Dwek, R. A., and Butters, T. D. (1994) N-Butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis, J. Biol. Chem. 269, 8362-8365.
108. Fan, C., Park, I. S., Walsh, C. T., and Knox, J. R. (1997) D-Alanine: D-alanine ligase: Phosphonate and phosphinate intermediates with wild type and the Y216F mutant, Biochemistry 36, 2531-2538.
109. Williams, J. W., Morrison, J. F., and Duggleby, R. G. (1979) Methotrexate, a high-affinity pseudosubstrate of dihydrofolate reductase, Biochemistry 18, 2567-2573.
110. McLean, J. E., Neidhardt, E. A., Grossman, T. H., and Hedstrom, L. (2001) Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase, Biochemistry 40, 2194-2200.
111. Baca, A. M., Sirawaraporn, R., Turley, S., Sirawaraporn, W., and Hol, W. G. (2000) Crystal structure of Mycobacterium tuberculosis 7,8-dihydropteroate synthase in complex with pterin monophosphate: New insight into the enzymatic mechanism and sulfa-drug action, J. Mol. Biol. 302, 1193-1212.
112. Arun, B., and Frenkel, E. P. (2001) Topoisomerase I inhibition with topotecan: Pharmacologic and clinical issues, Expert Opin. Pharmacother. 2, 491-505.
113. Anderson, V. E., and Osheroff, N. (2001) Type II topoisomerases as targets for quinolone antibacterials: Turning Dr. Jekyll into Mr. Hyde, Curr. Pharm. Des. 7, 337-353.
114. Villarreal, E. C. (2001) Current and potential therapies for the treatment of herpesvirus infections, Prog. Drug Res. Spec. No., 185-228.
115. Campbell, E. A., Korzheva, N., Mustaev, A., Murakami, K., Nair, S., Goldfarb, A., and Darst, S. A. (2001) Structural mechanism for rifampicin inhibition of bacterial rna polymerase, Cell 104, 901-912.
116. Stone, K. J., and Strominger, J. L. (1971) Mechanism of action of bacitracin: Complexation with metal ion and C55-isoprenyl pyrophosphate, Proc. Natl. Acad. Sci. U.S.A. 68, 3223-3227.
117. Vilcheze, C., Morbidoni, H. R., Weisbrod, T. R., Iwamoto, H., Kuo, M., Sacchettini, J. C., and Jacobs, W. R., Jr. (2000) Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis, J. Bacteriol. 182, 4059-4067.
118. Kiefel, M. J., and von Itzstein, M. (1999) Influenza virus sialidase: A target for drug discovery, Prog. Med. Chem. 36, 1-28.
119. Keam, S. J., and Goa, K. L. (2002) Fondaparinux sodium, Drugs 62, 1673-1685; discussion 1686-1677.
120. Bergstrom, J. D., Bostedor, R. G., Masarachia, P. J., Reszka, A. A., and Rodan, G. (2000) Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase, Arch. Biochem. Biophys. 373, 231-241.
121. Zimhony, O., Cox, J. S., Welch, J. T., Vilcheze, C., and Jacobs, W. R., Jr. (2000) Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis, Nat. Med. 6, 1043-1047.
122. Samulitis, B. K., Goda, T., Lee, S. M., and Koldovsky, O. (1987) Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine, Drugs Exp. Clin. Res. 13, 517-524.
123. Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., and Klein, P. S. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen, J. Biol. Chem. 276, 36734-36741.
124. Rodriguez-Barrios, F., and Gago, F. (2004) HTV protease inhibition: Limited recent progress and advances in understanding current pitfalls, Curr. Top. Med. Chem. 4, 991-1007.
125. + ATPase, Annu. Rev. Pharmacol. Toxicol. 35, 277-305.
126. Istvan, E. S. (2002) Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase, Am. Heart J. 144, S27-S32.
127. Sintchak, M. D., Fleming, M. A., Futer, O., Raybuck, S. A., Chambers, S. P., Caron, P. R., Murcko, M. A., and Wilson, K. P. (1996) Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid, Cell 85, 921-930.
128. Engler, H., Taurog, A., and Nakashima, T. (1982) Mechanism of inactivation of thyroid peroxidase by thioureylene drugs, Biochem. Pharmacol. 31, 3801-3806.
129. Brown, M. J., Mensah, L. M., Doyle, M. L., Broom, N. J., Osbourne, N., Forrest, A. K., Richardson, C. M., O'Hanlon, P. J., and Pope, A. J. (2000) Rational design of femtomolar inhibitors of isoleucyl tRNA synthetase from a binding model for pseudomonic acid-A, Biochemistry 39, 6003-6011.
130. Campbell, B. J., Forrester, L. J., Zahler, W. L., and Burks, M. (1984) β-Lactamase activity of purified and partially characterized human renal dipeptidase, J. Biol. Chem. 259, 14586-14590.
131. Bacchi, C. J., Nathan, H. C., Hutner, S. H., McCann, P. P., and Sjoerdsma, A. (1980) Polyamine metabolism: A potential therapeutic target in trypanosomes, Science 210, 332-334.
132. Fyfe, J. A., Miller, R. L., and Krenitsky, T. A. (1973) Kinetic properties and inhibition of orotidine 5′-phosphate decarboxylase. Effects of some allopurinol metabolites on the enzyme, J. Biol. Chem. 248, 3801-3809.
133. Cushman, D. W., Cheung, H. S., Sabo, E. F., and Ondetti, M. A. (1982) Development and design of specific inhibitors of angiotensin-converting enzyme, Am. J. Cardiol. 49, 1390-1394.
134. Mendelsohn, L. G., Shih, C., Schultz, R. M., and Worzalla, J. F. (1996) Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol, Invest. New Drugs 14, 287-294.
135. Scott, C. F., Wenzel, H. R., Tschesche, H. R., and Colman, R. W. (1987) Kinetics of inhibition of human plasma kallikrein by a site-specific modified inhibitor Arg15-aprotinin: Evaluation using a microplate system and comparison with other proteases, Blood 69, 1431-1436.
136. Markus, G., DePasquale, J. L., and Wissler, F. C. (1978) Quantitative determination of the binding of ∈-aminocaproic acid to native plasminogen, J. Biol. Chem. 253, 727-732.
137. Gierse, J. K., McDonald, J. J., Hauser, S. D., Rangwala, S. H., Koboldt, C. M., and Seibert, K. (1996) A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors, J. Biol. Chem. 271, 15810-15814.
138. Adams, J., Palombella, V. J., Sausville, E. A., Johnson, J., Destree, A., Lazarus, D. D., Maas, J., Pien, C. S., Prakash, S., and Elliott, P. J. (1999) Proteasome inhibitors: A novel class of potent and effective antitumor agents, Cancer Res. 59, 2615-2622.
139. Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., and Kuriyan, J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase, Science 289, 1938-1942.
140. Silva, D. J., Stubbe, J., Samano, V., and Robins, M. J. (1998) Gemcitabine 5′-triphosphate is a stoichiometric mechanism-based inhibitor of Lactobacillus leichmannii ribonucleoside triphosphate reductase: Evidence for thiyl radical-mediated nucleotide radical formation, Biochemistry 37, 5528-5535.
141. Maag, D., Castro, C., Hong, Z., and Cameron, C. E. (2001) Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin, J. Biol. Chem. 276, 46094-46098.
142. Sluis-Cremer, N., Temiz, N. A., and Bahar, I. (2004) Conformational changes in HIV-1 reverse transcriptase induced by non-nucleoside reverse transcriptase inhibitor binding, Curr. HIV Res. 2, 323-332.
143. Lee, W., McDonough, M. A., Kotra, L., Li, Z. H., Silvaggi, N. R., Takeda, Y., Kelly, J. A., and Mobashery, S. (2001) A 1.2-Å snapshot of the final step of bacterial cell wall biosynthesis, Proc. Natl. Acad. Sci. U.S.A. 98, 1427-1431.
144. Smith, T. W. (1989) The fundamental mechanism of inotropic action of digitalis, Therapie 44, 431-435.
145. Favre, B., and Ryder, N. S. (1997) Differential inhibition of fungal and mammalian squalene epoxidases by the benzylamine SDZ SBA 586 in comparison with the allylamine terbinafine, Arch. Biochem. Biophys. 340, 265-269.
146. Yoshida, Y., and Aoyama, Y. (1987) Interaction of azole antifungal agents with cytochrome P-45014DM purified from Saccharomyces cerevislae microsomes, Biochem. Pharmacol. 36, 229-235.
147. Lerabcke, B., Folsch, U. R., and Creutzfeldt, W. (1985) Effect of 1-desoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro, Digestion 31, 120-127.
148. Rydel, T. J., Ravichandran, K. G., Tulinsky, A., Bode, W., Huber, R., Roitsch, C., and Fenton, J. W., II (1990) The structure of a complex of recombinant hirudin and human α-thrombin, Science 249, 277-280.
149. Matthews, D. A., Appell, K., and Oatley, S. J. (1989) Crystal structure of Escherichia coli thymidylate synthase with FdUMP and 10-propargyl-5,8- dideazafolate, Adv. Enzyme Regul. 29, 47-60.
150. Toyoda, N., Kaptein, E., Berry, M. J., Harney, J. W., Larsen, P. R., and Visser, T. J. (1997) Structure-activity relationships for thyroid hormone deiodination by mammalian type I iodothyronine deiodinases, Endocrinology 138, 213-219.
151. Lookene, A., Skottova, N., and Olivecrona, G. (1994) Interactions of lipoprotein lipase with the active-site inhibitor tetrahydrolipstatin (Orlistat), Eur. J. Biochem. 222, 395-403.
152. Fitzpatrick, P. F. (1991) Steady-state kinetic mechanism of rat tyrosine hydroxylase, Biochemistry 30, 3658-3662.
153. Skarzynski, T., Mistry, A., Wonacott, A., Hutchinson, S. E., Kelly, V. A., and Duncan, K. (1996) Structure of UDP-N-acetylglucosamine enolpyruvyl transferase, an enzyme essential for the synthesis of bacterial peptidoglycan, complexed with substrate UDP-N-acetylglucosamine and the drug fosfomycin, Structure 4, 1465-1474.
154. Johnston, J. O. (1998) Aromatase inhibitors, Crit. Rev. Biochem. Mol. Biol. 33, 375-405.
155. Pearson, M. A., Michel, L. O., Hausinger, R. P., and Karplus, P. A. (1997) Structures of Cys319 variants and acetohydroxamate-inhibited Klebsiella aerogenes urease, Biochemistry 36, 8164-8172.
156. Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hortnagel, K., Pelz, H. J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G., Muller, C. R., Strom, T. M., and Oldenburg, J. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2, Nature 427, 537-541.
157. Cha, S., Agarwal, R. P., and Parks, R. E., Jr. (1975) Tight-binding inhibitors-II. Non-steady-state nature of inhibition of milk xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine deaminase by coformycin, Biochem. Pharmacol. 24, 2187-2197.
158. Singh, V., Evans, G. B., Lenz, D. H., Mason, J. M., Clinch, K., Mee, S., Painter, G. F., Tyler, P. C., Furneaux, R. H., Lee, J. E., Howell, P. L., and Schramm, V. L. (2005) Femtomolar transition state analogue inhibitors of 5′-methylthioadenosine/S-adenosylhomocysteine nucleosidase from Escherichia coli, J. Biol. Chem. (in press).